No Data
Jefferies Remains a Buy on Giant Biogene Holding Co. Ltd. (2367)
[Brokerage Focus] Guozheng International maintains a "Buy" rating for Giant Bio (02367) indicating that the company has multiple products that have consistently ranked TOP1 on the list.
Jinwu Financial News | Guozheng International's Research Reports indicate that Juzhi Biotechnology (02367) is expected to achieve revenue of 5.54 billion yuan in 2024, a year-on-year increase of 57.2%, primarily due to the continued strengthening of omnichannel marketing activities, steady growth of collagen sticks, and the successful launches of new products such as Kefu Mei focus cream, Keli Jin collagen film cream, and dressings. The company is expected to achieve a net income of 2.06 billion yuan in 2024, a year-on-year increase of 42.1%. The company's gross margin has declined by 1.5 percentage points compared to 2023, falling to 82.1%. It is noteworthy that the flagship brand Kefu Mei has increased by 62.9% year-on-year, while Keli Jin has seen a 3% increase.
Jefferies Adjusts Giant Biogene Holding's Price Target to HK$91 From HK$80, Keeps at Buy
Giant Biogene's Strong Revenue Growth and Strategic Expansion Drive Buy Rating
【Brokerage Focus】Soochow maintains a "Buy" rating for Giant Biological (02367), stating that its brand strength and product strength are leading, and future expansion in skin revitalization is promising.
Jingwu Financial News | Soochow Securities research indicates that Junzi Bio (02367) is projected to have a revenue of 5.54 billion yuan in 2024 (year-on-year +57.1%), with a net income of 2.06 billion yuan (year-on-year +42.1%), and adjusted net income of 2.15 billion yuan (year-on-year +46.5%), with the adjustments primarily related to Stock-based Incentive expenses. The company plans to distribute a total ordinary and special dividend of 1.2 yuan per share for 2024, with a payout ratio of 60%. Looking at the second half of 2024, the company is expected to have a revenue of 2.98 billion yuan (year-on-year +57.2%) and a net income of 1.08 billion yuan (year-on-year +37.5%).
If EPS Growth Is Important To You, Giant Biogene Holding (HKG:2367) Presents An Opportunity
